[{"address1": "Yalelaan 62", "city": "Utrecht", "zip": "3584 CM", "country": "Netherlands", "phone": "31 85 016 3100", "website": "https://www.lavatherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.", "fullTimeEmployees": 37, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen Allen Hurly M.B.A., M.Sc.", "age": 55, "title": "CEO, President & Executive Director", "yearBorn": 1968, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Fred M. Powell CPA", "age": 62, "title": "Chief Financial Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hans  van der Vliet M.D., Ph.D.", "age": 49, "title": "Chief Scientific Officer", "yearBorn": 1974, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Garabedian J.D.", "age": 47, "title": "General Counsel & Corporate Secretary", "yearBorn": 1976, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Wouter van Hunnik", "title": "VP & Head of Human Resources", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ton  Adang Ph.D.", "age": 62, "title": "Chief Development Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1965, "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 2.03, "open": 2.06, "dayLow": 1.98, "dayHigh": 2.1, "regularMarketPreviousClose": 2.03, "regularMarketOpen": 2.06, "regularMarketDayLow": 1.98, "regularMarketDayHigh": 2.1, "beta": 0.528, "forwardPE": -1.1061453, "volume": 82832, "regularMarketVolume": 82832, "averageVolume": 78173, "averageVolume10days": 123910, "averageDailyVolume10Day": 123910, "bid": 1.98, "ask": 2.08, "bidSize": 100, "askSize": 100, "marketCap": 52058556, "fiftyTwoWeekLow": 1.131, "fiftyTwoWeekHigh": 6.47, "priceToSalesTrailing12Months": 4.1523933, "fiftyDayAverage": 2.2107, "twoHundredDayAverage": 2.09048, "currency": "USD", "enterpriseValue": -36382468, "profitMargins": -2.28021, "floatShares": 12086781, "sharesOutstanding": 26292200, "sharesShort": 75796, "sharesShortPriorMonth": 84228, "sharesShortPreviousMonthDate": 1717113600, "dateShortInterest": 1719532800, "sharesPercentSharesOut": 0.0029, "heldPercentInsiders": 0.28722, "heldPercentInstitutions": 0.32358003, "shortRatio": 1.0, "shortPercentOfFloat": 0.0047, "impliedSharesOutstanding": 26292200, "bookValue": 1.927, "priceToBook": 1.0275038, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -28587000, "trailingEps": -1.06, "forwardEps": -1.79, "enterpriseToRevenue": -2.902, "enterpriseToEbitda": 1.172, "52WeekChange": 0.053191543, "SandP52WeekChange": 0.19608545, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "LVTX", "underlyingSymbol": "LVTX", "shortName": "LAVA Therapeutics N.V.", "longName": "LAVA Therapeutics N.V.", "firstTradeDateEpochUtc": 1616765400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f272303e-4305-36b0-b7df-26c82acd7c44", "messageBoardId": "finmb_546792242", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.98, "targetHighPrice": 11.0, "targetLowPrice": 6.0, "targetMeanPrice": 7.25, "targetMedianPrice": 6.0, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 94573000, "totalCashPerShare": 3.597, "ebitda": -31035000, "totalDebt": 6132000, "quickRatio": 7.329, "currentRatio": 7.421, "totalRevenue": 12537000, "debtToEquity": 12.103, "revenuePerShare": 0.467, "returnOnAssets": -0.1689, "returnOnEquity": -0.45397, "freeCashflow": -21961250, "operatingCashflow": -31762000, "revenueGrowth": 4.712, "grossMargins": 0.79643995, "ebitdaMargins": -2.47547, "operatingMargins": -0.27918, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-25"}]